Ignite Creation Date:
2025-12-25 @ 5:02 AM
Ignite Modification Date:
2025-12-26 @ 4:03 AM
Study NCT ID:
NCT06238518
Status:
RECRUITING
Last Update Posted:
2024-02-02
First Post:
2024-01-16
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Intravascular Lithotripsy Versus Conventional Therapy for Severely Calcified Coronary Artery Lesions
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Prospective, 1:1 randomized, controlled, multicenter trial to assess effectiveness and safety of adding IVL to Conventional Therapy compared to Conventional Therapy only in calcified coronary lesions.'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 220}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2024-01-05', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-01', 'completionDateStruct': {'date': '2025-03-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-01-25', 'studyFirstSubmitDate': '2024-01-16', 'studyFirstSubmitQcDate': '2024-01-25', 'lastUpdatePostDateStruct': {'date': '2024-02-02', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2024-02-02', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-12-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Suboptimal stent deployment', 'timeFrame': 'Measured by the data collected at the end of the PCI procedure', 'description': 'Suboptimal stent deployment is defined as fulfilling any of the following criteria: minimum stent area (MSA) ≤4.5mm2 (by OCT), MSA/mean reference lumen area ≤80%, flow-limiting dissections, or incomplete stent apposition (axial distance ≥0.4 mm and length ≥1 mm)'}, {'measure': 'Stent delivery failure', 'timeFrame': 'Measured by the data collected at the end of the PCI procedure'}, {'measure': 'Cardiac cause death', 'timeFrame': '1, 12, 36, and 60 months'}, {'measure': 'Target vessel myocardial infarction (TV-MI)', 'timeFrame': '1, 12, 36, and 60 months'}, {'measure': 'Clinically indicated target lesion revascularization (CI-TLR)', 'timeFrame': '1, 12, 36, and 60 months'}, {'measure': 'Clinically indicated target vessel revascularization (CI-TVR)', 'timeFrame': '1, 12, 36, and 60 months'}, {'measure': 'All cause death', 'timeFrame': '1, 12, 36, and 60 months'}, {'measure': 'Any stroke', 'timeFrame': '1, 12, 36, and 60 months'}, {'measure': 'Any MI', 'timeFrame': '1, 12, 36, and 60 months'}, {'measure': 'Any revascularisation', 'timeFrame': '1, 12, 36, and 60 months'}, {'measure': 'Patient-oriented composite endpoint (PoCE)', 'timeFrame': '1, 12, 36, and 60 months', 'description': 'Patient-oriented composite endpoint (PoCE) is defined as all-cause death, any stroke, any MI, and any clinically indicated revascularisation'}, {'measure': 'Definite/Probable Stent thrombosis rates', 'timeFrame': '1, 12, 36, and 60 months', 'description': 'According to ARC-II classification'}, {'measure': 'Peri-procedural MI', 'timeFrame': '48 hours', 'description': 'According to SCAI definition'}, {'measure': 'Peri-procedural major adverse events', 'timeFrame': '30 days', 'description': 'Peri-procedural major adverse events were defined as a composite of the procedure of periprocedural MI, flow-limiting dissections, perforation/rupture, acute occlusion, slow-flow/no-reflow, ventricular tachycardia/ventricular fibrillation within 30 days'}, {'measure': 'Acute gain', 'timeFrame': 'Measured by the data collected at the end of the PCI procedure', 'description': 'Acute gain is the difference between post- and pre-procedural minimal lumen diameter (MLD) as measured in (preferable) identical orthogonal views by OCT (MLDpost - MLDpre)'}, {'measure': 'The difference between post- and pre-procedural FFR/IMR', 'timeFrame': 'Measured by the data collected at the end of the PCI procedure', 'description': 'FFR/IMR can be measured either by wire or derived from coronary angiography'}, {'measure': 'Procedure time of the PCI', 'timeFrame': 'Measured by the data collected at the end of the PCI procedure'}, {'measure': 'Radiation dose of the PCI', 'timeFrame': 'Measured by the data collected at the end of the PCI procedure'}, {'measure': 'Contrast volume', 'timeFrame': 'Measured by the data collected at the end of the PCI procedure'}, {'measure': 'Calcium fracture', 'timeFrame': 'Measured by the data collected at the end of the PCI procedure'}, {'measure': 'Angiographic success', 'timeFrame': 'Measured by the data collected at the end of the PCI procedure', 'description': 'Angiographic success is defined as the ability of the allocated treatment to produce residual stenosis \\<20% after stenting without serious angiographic complications (severe dissection impairing flow \\[type D-F\\], perforation, abrupt closure, persistent slow flow, or no-reflow).'}, {'measure': 'Strategy success', 'timeFrame': 'Measured by the data collected at the end of the PCI procedure', 'description': 'Strategy success is defined as Angiographic success without treatment crossover or stent loss'}, {'measure': 'Clinical (Procedural) success', 'timeFrame': '1 month', 'description': 'Clinical (Procedural) success is defined as Device success without the occurrence of in-hospital cardiovascular death, target-vessel myocardial infarction, or clinically indicated target vessel revascularization.'}, {'measure': 'Coronary flow velocity', 'timeFrame': 'Measured by the data collected at the end of the PCI procedure', 'description': 'Coronary flow velocity is measured by Quantitative Flow Ratio (QFR)'}, {'measure': 'TIMI Flow', 'timeFrame': 'Measured by the data collected at the end of the PCI procedure'}, {'measure': 'Stent malapposition', 'timeFrame': 'Measured by the data collected at the end of the PCI procedure'}, {'measure': 'Stent volume / reference lumen volume', 'timeFrame': 'Measured by the data collected at the end of the PCI procedure', 'description': 'Assessed by OCT'}, {'measure': 'Mean stent area / Mean reference lumen area', 'timeFrame': 'Measured by the data collected at the end of the PCI procedure', 'description': 'Assessed by OCT Assessed by OCT'}], 'primaryOutcomes': [{'measure': 'Final stent expansion (%) assessed by OCT', 'timeFrame': 'Measured by the data collected at the end of the PCI procedure', 'description': 'The primary efficacy endpoint of the trial is the Final stent expansion %, defined as the minimum stent area (MSA) / mean reference lumen area assessed by OCT.'}, {'measure': 'Target vessel failure (TVF)', 'timeFrame': '1, 12, 36, and 60 months', 'description': 'The primary safety endpoint of the trial is target vessel failure (TVF), defined as a non-hierarchical composite endpoint of cardiovascular death, target-vessel myocardial infarction (TV-MI), and clinically indicated target vessel revascularization (CI-TVR).'}], 'secondaryOutcomes': [{'measure': 'Major cardiovascular adverse events', 'timeFrame': '1, 12, 36, and 60 months', 'description': 'Major adverse cardiovascular events (MACE) is defined as a hierarchical composite of cardiovascular death, target-vessel myocardial infarction, clinically indicated target vessel revascularization, stent delivery failure, and suboptimal stent deployment.\n\nThe between-group difference in terms of MACE will be compared using the Win Ratio approach in the abovementioned order.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Severely Calcified Coronary Stenoses', 'Intravascular Lithotripsy', 'percutaneous coronary intervention'], 'conditions': ['Severely Calcified Coronary Stenoses', 'De Novo Stenosis']}, 'descriptionModule': {'briefSummary': 'Percutaneous coronary intervention (PCI) encounters challenges with calcified coronary lesions, leading to potential issues such as failed balloon dilatation, incomplete stent expansion, and increased risks of adverse events post-PCI, including stent restenosis and thrombosis.\n\nIntravascular lithotripsy (IVL), a novel approach for severely calcified coronary lesion preparation, has shown promising preliminary outcomes. Combining IVL with conventional approaches, such as Rotational atherectomy (RA), non-compliant balloons, or cutting balloons, may associated with additional benefit than conventional approaches only in terms of better stent expansion and lower long-term adverse events.\n\nThis pilot randomized trial aims to investigate whether combining IVL to conventional therapy surpasses the efficacy of conventional approaches alone. The primary effectiveness endpoint is final stent expansion assessed by post-procedure optical coherence tomography (OCT), and the primary safety endpoint is target lesion failure (TVF). The trial seeks to provide valuable insights into the optimal approach for managing severely calcified coronary lesions during PCI.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nGeneral Inclusion Criteria:\n\n1. Patients with acute or chronic coronary artery syndrome indicated for PCI with stenting.\n2. Able to understand and provide informed consent and comply with all study procedures\n\nAngiographic Inclusion Criteria:\n\n1. Native and de novo coronary artery disease\n2. Lesion navigable by a 0.014" guidewire.\n3. Target lesion is severely calcified, meeting one of the following criteria:\n\n * Presence of calcium ≥ 270°, lengths ≥ 5mm, and thickness ≥ 0.5mm at one cross-section as assessed by OCT\n * If the OCT catheter is unable to pass through the target lesion after dilatation due to calcification or tortuosity, and the target lesion is severely calcified on both sides of the arterial wall during angiography, with the length of the calcification \\>15 mm, the lesion will be recognized as a severely calcified lesion, meeting the criteria for enrollment\n\nExclusion Criteria:\n\nGeneral Exclusion Criteria:\n\n1. Patients under 18 years of age.\n2. Incapable of providing informed consent.\n3. Female patients who are pregnant or nursing (a pregnancy test must be conducted within 7 days before the index procedure for women of childbearing potential, as per local practice).\n4. Concurrent medical conditions with a life expectancy of less than 1 year.\n5. Hemodynamic instability.\n6. Known contraindications to medications such as Heparin, anticoagulation, antiplatelet drugs, or contrast.\n7. Active bleeding.\n8. New-onset stroke or transient ischemic attack (TIA) within 90 days prior to enrollment.\n9. Severe renal dysfunction (eGFR ≤ 30 ml/min).\n10. Patients scheduled to undergo cardiac intervention or cardiac surgery within 30 days of the index procedure.\n11. Recent ST-segment elevation myocardial infarction (STEMI) within 7 days or recent cardiogenic shock.\n12. Lesions located in surgical conduits.\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel exhibiting C-F type dissection.\n2. Thrombosis observed by angiography or OCT.\n3. Presence of an aneurysm within 10 mm of the target lesion.\n4. Left main ostial lesion'}, 'identificationModule': {'nctId': 'NCT06238518', 'acronym': 'REC-CHIPCAC', 'briefTitle': 'Intravascular Lithotripsy Versus Conventional Therapy for Severely Calcified Coronary Artery Lesions', 'organization': {'class': 'OTHER', 'fullName': 'Xijing Hospital'}, 'officialTitle': 'Intravascular Lithotripsy Versus Conventional Therapy for Severely Calcified Coronary Artery Lesions: an Investigator-initiated, Open-label, Multicentre, Randomised, Superiority Trial', 'orgStudyIdInfo': {'id': 'KY20232390-C-1'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Conventional lesion preparation plus Intravascular Lithotripsy strategy', 'description': 'IVL could be performed before, amidst, or after Conventional lesion preparation therapy; However, the use of IVL treatment is mandatory.', 'interventionNames': ['Procedure: Intravascular Lithotripsy', 'Procedure: Conventional lesion preparation strategy']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Conventional lesion preparation strategy', 'description': 'Conventional lesion preparation strategy includes the use of Compliant, noncompliant, cutting, or scoring balloons, Excimer laser coronary atherectomy, or Rotational atherectomy at the discretion of the operator.', 'interventionNames': ['Procedure: Conventional lesion preparation strategy']}], 'interventions': [{'name': 'Intravascular Lithotripsy', 'type': 'PROCEDURE', 'description': 'The size of the IVL balloon catheter is selected in a 1:1 ratio to the distal reference vessel diameter. The balloon catheter is then inflated to 4 atm, and 10 impulses are delivered. Subsequently, the balloon is inflated to 8 atm and then deflated to re-establish blood flow. Up to 100 impulses can be delivered, and the balloon can be repositioned within the lesion. In cases involving multiple lesions with different reference vessel diameters, various sizes of IVL balloons may be employed. If the IVL balloon catheter is unable to pass through the lesion, pre-dilatation can be performed using a smaller diameter noncompliant balloon or rotational atherectomy.', 'armGroupLabels': ['Conventional lesion preparation plus Intravascular Lithotripsy strategy']}, {'name': 'Conventional lesion preparation strategy', 'type': 'PROCEDURE', 'description': 'Conventional lesion preparation strategy includes the use of Compliant, noncompliant, cutting, or scoring balloons, Excimer laser coronary atherectomy, or Rotational atherectomy at the discretion of the operator.', 'armGroupLabels': ['Conventional lesion preparation plus Intravascular Lithotripsy strategy', 'Conventional lesion preparation strategy']}]}, 'contactsLocationsModule': {'locations': [{'zip': '710032', 'city': "Xi'an", 'state': 'Shannxi', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Chao Gao', 'role': 'CONTACT', 'email': 'woshigaochao@gmail.com'}], 'facility': 'Ling Tao', 'geoPoint': {'lat': 34.25833, 'lon': 108.92861}}], 'centralContacts': [{'name': 'Chao Gao,, M.D, Ph.D', 'role': 'CONTACT', 'email': 'woshigaochao@gmail.com', 'phone': '+86-18629551066'}, {'name': 'Ruining Zhang, BSc', 'role': 'CONTACT', 'email': 'ruining-zhang@qq.com', 'phone': '+86-15802990370'}], 'overallOfficials': [{'name': 'Ling Tao, M.D, Ph.D.', 'role': 'STUDY_CHAIR', 'affiliation': 'Xijing Hospital'}, {'name': 'Chao Gao, M.D, Ph.D.', 'role': 'STUDY_CHAIR', 'affiliation': 'Xijing Hospital'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Xijing Hospital', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Professor in Cardiology, Director of the department of Cardiology', 'investigatorFullName': 'LingTao', 'investigatorAffiliation': 'Xijing Hospital'}}}}